BrainsWay Announces New Clinical Support Program for Physicians Treating Obsessive-Compulsive Disorder: – “BrainsWay OCD Launchpad to...

BrainsWay Expands Intellectual Property Position by Obtaining Rights to Multi-Channel Transcranial Magnetic Stimulation Patent Portfolio...

Enters into an Agreement to Distribute its Deep Transcranial Magnetic Stimulation System in South Korea. JERUSALEM, February 20, 2019 –...

BrainsWay Receives FDA 510(k) Clearance for Use of its Next-Generation Stimulator for the Treatment of Obsessive Compulsive Disorder...

BrainsWay Receives PMDA Approval in Japan of Deep Transcranial Magnetic Stimulation System for Treatment of Major Depressive Disorder...

BrainsWay Selected to Participate in FDA Innovation Challenge: Devices to Prevent and Treat Opioid Use Disorder Company’s Deep...

Press the link to hear the conference call

BrainsWay to Showcase FDA-Cleared Deep Transcranial Magnetic Stimulation System for the Treatment of Obsessive-Compulsive Disorder at...

BrainsWay to Showcase Deep Transcranial Magnetic Stimulation System for the Treatment of Obsessive-Compulsive Disorder at the 2018 Annual...

BrainsWay Announces First Shipments of Deep Transcranial Magnetic Stimulation Helmets for the Treatment of Obsessive-Compulsive Disorder...

Second quarter revenues of $3.7 million represent a quarterly record and a 57% increase over second quarter 2017 Recently announced FDA...

BrainsWay Receives First Ever FDA Clearance of a Non-Invasive Device for Treatment of Obsessive Compulsive Disorder BrainsWay’s deep...

BrainsWay and Cohen Veterans Bioscience Announce Biomarker Research Collaboration in Post Traumatic Stress Disorder Unique Biomarkers...

First quarter revenues of $3.6 million represent a quarterly record and a 68% increase over first quarter 2017 Increased market demand...

NEWTON, Mass., May 23, 2018 (GLOBE NEWSWIRE) — Achieve TMS, the largest U.S. provider of BrainsWay’s Deep Transcranial Magnetic...

BrainsWay Receives FDA Clearance of Next Generation Stimulator, Enhancing Its Current Deep Transcranial Magnetic Stimulation (Deep TMS)...

Phoenix Group becomes 7% shareholder. financing strengthens BrainsWay’s balance sheet and provides strong support for continued growth...

ncreased market demand and new leasing model continue to generate significant sales growth Recently signed contracts increased total...

Sponsor Editoriial Board “The transition to focusing on the leasing business model helps us continue increasing the revenues ‎we receive...

BrainsWay Reports Continued Successful Implementation of its New Business Model in Second Quarter of 2017 Backlog revenues due to future...